Pharmacopsychiatry 2008; 41(5): 203-204
DOI: 10.1055/s-2008-1078747
Letter

© Georg Thieme Verlag KG Stuttgart · New York

Choreatic Symptoms During and After Treatment with Paliperidone and Escitalopram

R. Hüther 1 , C. Gebhart 1 , S. Mirisch 1 , J. Bäuml 1 , H. Förstl 1
  • 1Department of Psychiatry and Psychotherapy, TU Munich, München, Germany
Further Information

Publication History

received 24.10.2007 revised 01.04.2008

accepted 04.04.2008

Publication Date:
01 September 2008 (online)

Paliperidone, the first orally applicable atypical neuroleptic marketed as an extended-release preparation, is generally well tolerated [1] [5]. Over the last weeks, we have observed several young patients with schizophrenia, who showed significant akathisia during paliperidone treatment. Here we report the case of a depressed and psychotic patient who developed a dramatic choreatic syndrome during treatment with escitalopram and paliperidone.

References

  • 1 Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.  Schizophrenia Res. 2007;  93 117-130
  • 2 Dremencov E, El Mansari M, Blier P. Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons.  Psychopharmacology. 2007;  194 63-72
  • 3 Förstl H, Pohlmann-Eden B. Amplitudes of somatosensory evoked potentials reflect cortical hyperexcitability in antidepressant-induced myoclonus.  Neurology. 1990;  40 924-926
  • 4 Karlsson P, Hargarter L, Dencker E. et al . Pharmacokinetics and dopamine D2 and serotonin 5-HT2a receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies.  Pharmacopsychiatry. 2007;  40 , 227
  • 5 Meltzer H, Hargarter L, Kramer M. et al . Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week placebo-controlled studies.  Pharmacopsychiatry. 2007;  40 , 222
  • 6 Saito M, Yasui-Furukori N, Nakagami T, Furukori H, Kaneko S. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.  J Clin Psychopharmacol. 2005;  25 527-532

Correspondence

H. Förstl

Department of Psychiatry and Psychotherapy

TU Munich

Ismaningerstr. 22

81675 München

Germany

Phone: +49/89/4140 42 00

Fax: +49/89/4140 48 37

Email: Hans.foerstl@lrz.tu-muenchen.de

    >